港股異動丨亞盛醫藥-B(6855.HK)高開4.53% 奧雷巴替尼治療耐藥CML上市申請獲NMPA受理並納入優先審評
格隆匯7月20日丨亞盛醫藥-B(6855.HK)高開4.53%,報18港元,總市值47億港元。亞盛醫藥宣佈,原創1類新藥奧雷巴替尼(商品名:耐立克®)的上市申請已獲中國國家藥品監督管理局(NMPA)藥品審評中心(CDE)受理並被納入優先審評程序,用於治療一代和二代酪氨酸激酶抑制劑(TKIs)耐藥和╱或不耐受的慢性髓細胞白血病慢性期(CML-CP)患者,將支持耐立克®獲得完全批准。這是耐立克®繼2021年附條件批准上市後的又一重要進展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.